CAIRO: Egypt has overcome the peak of the second wave of coronavirus, according to the president’s health adviser Mohammed Awad Taj El-Din.

He said that new coronavirus cases were currently decreasing, pointing to the continued presence of the disease, but that precautionary measures still needed to be followed in order to reduce infection rates among people.

“The second wave was high, but there is a decrease in new cases. As for cases that need hospitals or ventilators, their numbers have decreased,” he added.

Taj El-Din regarded the fluctuation in the number of cases, whether it was an increase or decrease, as natural because COVID-19 symptoms appeared in some people up to two weeks after they had contracted the virus.

FASTFACT

Egypt on Tuesday morning received 300,000 doses of the Chinese Sinopharm coronavirus vaccine, the second batch from the company after the first shipment of 50,000 doses in December.

He said that intensive care rooms were available as were respirators and, as long as there was a decline in the number of new cases, there was no reason to be worried.

Egypt on Tuesday morning received 300,000 doses of the Chinese Sinopharm coronavirus vaccine, the second batch from the company after the first shipment of 50,000 doses in December.

It also received 50,000 doses of the AstraZeneca vaccine in early February, as part of its program to vaccinate health workers.

Taj El-Din said the antibodies produced by the coronavirus vaccines could last up to nine months, and the immunity to coronavirus that was produced by the vaccines, the period in which people were protected from contracting the virus again, varied between three and nine months.

He explained that the immunity period varied from one person to another, as some vaccines gave 86 percent protection from the virus while others gave up to 90 percent.

He said it was necessary to limit gatherings and follow precautionary measures during Ramadan so that there was no new coronavirus wave in Egypt.

Copyright: Arab News © 2021 All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info).

Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.